+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "APL 130277"

From
  • 2 Results (Page 1 of 1)
Loading Indicator

The APL 130277 market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. APL 130277 is a drug developed by Aptinyx Inc. that is used to treat post-traumatic stress disorder (PTSD). It is a novel, non-opioid, small molecule drug that works by modulating the activity of the NMDA receptor, which is involved in the regulation of fear and anxiety. The drug has been tested in clinical trials and is currently in Phase 3 clinical development. The APL 130277 market is highly competitive, with several companies developing similar drugs. These include Allergan, Johnson & Johnson, Merck, Pfizer, and GlaxoSmithKline. Other companies involved in the market include NeuroRx, Inc., Neurocrine Biosciences, Inc., and Tonix Pharmaceuticals Holding Corp. Show Less Read more